A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100
Phase 2, open-label, 16-week, treat-to-target RCT (n =205 with type 2 diabetes, HbA1c 7–10%) found treatment with this novel once-weekly basal insulin analogue was efficacious and well tolerated across all three titration algorithms investigated.
Source:
Diabetes Care
SPS commentary:
A related study which investigated switching from insulin glargine U100 to icodec found increased time in target glucose range as assessed by continuous glucose monitoring in those switched vs unswitched (72.9% vs 65.0%, p<0.05).
Insulin icodec is a basal insulin analogue designed for once-weekly administration that is in development for the treatment of diabetes. Slow release of this modified insulin from an albumin depot, together with amino acid changes which make it more resistant to enzyme degradation, result in a prolonged half life of 196 hours.